These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 18410995)

  • 1. Molecular evidence demonstrating local treatment failure is the source of distant metastases in some patients treated for breast cancer.
    Vicini FA; Goldstein NS; Wallace M; Kestin L
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):689-94. PubMed ID: 18410995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular clonality determination of ipsilateral recurrence of invasive breast carcinomas after breast-conserving therapy: comparison with clinical and biologic factors.
    Goldstein NS; Vicini FA; Hunter S; Odish E; Forbes S; Kraus D; Kestin LL
    Am J Clin Pathol; 2005 May; 123(5):679-89. PubMed ID: 15981807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular clonality relationships in initial carcinomas, ipsilateral breast failures, and distant metastases in patients treated with breast-conserving therapy: evidence suggesting that some distant metastases are derived from ipsilateral breast failures and that metastases can metastasize.
    Goldstein NS; Vicini FA; Hunter S; Odish E; Forbes S; Kestin LL
    Am J Clin Pathol; 2005 Jul; 124(1):49-57. PubMed ID: 15923174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term patterns of in-breast failure in patients with early stage breast cancer treated with breast-conserving therapy: a molecular based clonality evaluation.
    McGrath S; Antonucci J; Goldstein N; Wallace M; Mitchell C; Grills I; Jolly S; Kestin L; Vicini F
    Am J Clin Oncol; 2010 Feb; 33(1):17-22. PubMed ID: 19636236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy.
    Vicini FA; Antonucci JV; Goldstein N; Wallace M; Kestin L; Krauss D; Kunzmann J; Gilbert S; Schell S
    Cancer; 2007 Apr; 109(7):1264-72. PubMed ID: 17372920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients.
    Goldstein NS; Kestin L; Vicini F
    Am J Clin Pathol; 2003 Oct; 120(4):500-27. PubMed ID: 14560562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monomorphic epithelial proliferations: characterization and evidence suggesting they are the pool of partially transformed lesions from which some invasive carcinomas arise.
    Goldstein NS; Kestin LJ; Vicini FA
    Am J Clin Pathol; 2007 Dec; 128(6):1023-34. PubMed ID: 18024329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
    Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP
    Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermal lymphatic invasion and inflammatory breast cancer are independent predictors of outcome after postmastectomy radiation.
    Abramowitz MC; Li T; Morrow M; Sigurdson ER; Anderson P; Nicolaou N; Freedman G
    Am J Clin Oncol; 2009 Feb; 32(1):30-3. PubMed ID: 19194121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells.
    Robertson FM; Simeone AM; Mazumdar A; Shah AH; McMurray JS; Ghosh S; Cristofanilli M
    J Exp Ther Oncol; 2008; 7(4):299-312. PubMed ID: 19227010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory breast cancer: patient advocate view.
    Mason G; Johnson O
    Semin Oncol; 2008 Feb; 35(1):87-91. PubMed ID: 18308150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer.
    Goodale D; Phay C; Brown W; Gray-Statchuk L; Furlong P; Lock M; Chin-Yee I; Keeney M; Allan AL
    Cytometry B Clin Cytom; 2009 Mar; 76(2):107-17. PubMed ID: 18727054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in patterns of failure in patients treated with accelerated partial breast irradiation versus whole-breast irradiation: a matched-pair analysis with 10-year follow-up.
    Antonucci JV; Wallace M; Goldstein NS; Kestin L; Chen P; Benitez P; Dekhne N; Martinez A; Vicini F
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):447-52. PubMed ID: 19058921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after breast conservation treatment with radiation in women with prior nonbreast malignancy and subsequent invasive breast carcinoma.
    Nemani D; Vapiwala N; Hwang WT; Solin LJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1055-60. PubMed ID: 18929447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
    Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
    J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors predicting in-breast tumor recurrence after breast-conserving surgery.
    Mechera R; Viehl CT; Oertli D
    Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cosmesis after lumpectomy and brachytherapy in the management of carcinoma of the previously irradiated breast.
    Trombetta M; Julian TB; Werts DE; McWilliams W; Kim Y; Miften M; Parda D
    Am J Clin Oncol; 2009 Jun; 32(3):314-8. PubMed ID: 19451803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.